Opendata, web and dolomites

BiomStrip SIGNED

Over-The-Counter Test Strip for Early-Stage Cancer Screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BiomStrip project word cloud

Explore the words cloud of the BiomStrip project. It provides you a very rough idea of what is the project "BiomStrip" about.

scalability    license    granting    platform    empowering    flora    device    trl6    spread    rate    biomstrip    once    business    detecting    indicator    pregnancy    survival    companies    drops    dysbiosis    introduces    point    bought    types    effectiveness    options    vital    suffers    deaths    grown    sensitivity    market    strategies    accurate    plan    counter    covered    tests    diseases    workplan    death    patients    minimised    gradually    highest    drastically    histological    pioneering    detect    offers    pathophysiological    diagnostics    building    breast    globally    feasibility    entry    detection    stage    burdens    ultimately    screening    microbial    capacity    fastest    keeping    solution    sme    biomarker    transform    difficult    tech    fashion    sensitive    commercialisation    sums    diagnostic    super    ipr    causing    resource    strategic    disease    healthcare    diagnosed    onset    carry    form    therapy    successfully    cancer    effort    subsequently    invasive    disruptive    overheads    alleviating    markets    costly    therapeutical    partnership    model    explosive    breakthrough    time    compliance    selectively    preventive    gut    designed    validation    risk    vastly    engineer    handled    intensity    multinational    spent   

Project "BiomStrip" data sheet

The following table provides information about the project.

Coordinator
LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG 

Organization address
address: GARDONYI GEZA UTCA 39
city: DEBRECEN
postcode: 4032
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Hungary [HU]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LOGODERM OKTATO ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG HU (DEBRECEN) coordinator 50˙000.00

Map

 Project objective

Cancer is the second leading cause of death globally, causing 1 in 6 deaths. If cancer is diagnosed at early stage, it is highly likely to be treated successfully. Once it has grown and spread, therapy is vastly more difficult and costly, and survival rate drops rapidly. Screening is a vital healthcare element for early detection but suffers from burdens of cost, capacity, compliance, and detection sensitivity problems. BiomStrip introduces a pioneering screening solution that can carry out cancer screening in the fashion of the common pregnancy tests. Building on our recent breakthrough results in biomarker validation granting TRL6 stage, we have designed a diagnostic device that is low-cost, non-invasive, accurate, can be handled by consumer, and bought over-the counter. The diagnostic method is based on detecting dysbiosis of gut microbial flora, a highly sensitive indicator of pathophysiological processes able to selectively show disease onset at super-early stage, even before histological changes are observable. The method is ultimately able to detect most cancer types and even other diseases, making it a future platform technology. For highest scalability, fastest time-to-market, explosive growth, low resource-intensity, and minimised risk and overheads, we will license production and commercialisation to established multinational companies, keeping our focus as high-tech SME. Breast cancer will be our market entry point and other diseases will be covered subsequently form own resources. To engineer this Workplan, a feasibility study will assess entry use cases and their markets, analyse business model and partnership options, and evaluate IPR strategies in a Strategic Business Plan. The disruptive approach offers to transform cancer screening from top-down to bottom-up: empowering patients, gradually alleviating healthcare systems large effort and sums spent on preventive cancer diagnostics, and drastically improving therapeutical effectiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BIOMSTRIP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BIOMSTRIP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More  

NextGen-O2k (2019)

Next Generation Instrument for In-Depth Analysis of Mitochondrial Fitness

Read More  

PD-Watch (2019)

Wearable technology for the selective detection and continuous monitoring of movement disorders related to Parkinson’s disease

Read More